Om avsnittet
In this episode we revisit SARS-CoV-2 research and take a look at new studies that have built on the work completed early in the pandemic. We focus on a story featuring Plitidepsin, a cancer drug that is being repurposed and tested in clinical trials to treat SARS-CoV-2 infection. This discussion features B3 hosts Gina, Mehdi and Robyn who are joined by scientists Dr. Lucy Thorne and Dr. Ann-Kathrin Reuschl. You can find the first article that was published in Science, “Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A” here: https://science.sciencemag.org/content/371/6532/926 You can find the second pre-print article, “Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant” at bioRxiv here: https://www.biorxiv.org/content/10.1101/2021.01.24.427991v2 If you have any questions or comments you can email us at biologistsbeingbasic@gmail.com or find us on twitter or instagram (@biosbeingbasic). See our website for more details (http://biosbeingbasic.podomatic.net).